Clinical Trial Update: Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery [Phase 2]

View source ↗

Summary

Phase 2 study evaluating AL208 for safety, tolerability, and effect on mild cognitive impairment after CABG surgery has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Drugs mentioned

• AL208

Snippet

Sponsor: Allon Therapeutics | Conditions: Mild Cognitive Impairment | Phase 2 | Status: COMPLETED